Urinary Obstruction News and Research

RSS

AI models fall short in medical coding accuracy

State-of-the-art artificial intelligence systems known as large language models (LLMs) are poor medical coders, according to researchers at the Icahn School of Medicine at Mount Sinai.

22 Apr 2024

Optilume BPH Catheter System offers a safe and effective treatment for benign prostatic hyperplasia

Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a randomized trial in the September issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA).

10 Aug 2023

Study finds new drug combination to be more effective against complicated urinary tract infections

An international study led by a Rutgers scientist comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially against stubborn, drug-resistant infections.

25 Oct 2022

Pregnancy increases the risk of first-time symptomatic kidney stone

Though researchers have long known that several physiological and anatomical changes occur during pregnancy that can contribute to kidney stone formation, evidence of the link has been lacking. But now Mayo Clinic researchers believe they have that evidence.

15 Apr 2021

Researchers describe histological features of urinary obstruction in humans for the first time

A research group from the Medical University of Vienna has successfully described the histological features of urinary obstruction in humans the first time.

13 Aug 2019

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.

8 Jun 2018

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease.

4 Sep 2012

Surprising life-quality benefit from early prostate cancer treatment

Treatment of early-stage prostate cancer may also improve quality of life if patients have previously suffered from obstructive urinary symptoms before undergoing treatment, shows US research.

30 May 2012

Prostate size and other neglected factors influence prostate cancer treatment satisfaction

Men with prostate cancer and their partners face difficult decisions regarding treatment, and accurate information regarding expected outcomes can be hard to find, according to results of a multi-center study published Wednesday in the New England Journal of Medicine.

20 Mar 2008

New research could affect future treatment options for prostate cancer

Two new studies on the treatment of prostate cancer could well affect future treatment options for patients.

8 Nov 2006